Process Development and Scale Up of a Selective JAK3 Covalent Inhibitor PF-06651600-Reference-Cited by-同舟云学术

Process Development and Scale Up of a Selective JAK3 Covalent Inhibitor PF-06651600

Published:2019-07-19 Issue:9 Volume:23 Page:1872-1880
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Tao Yong^ORCID,McWilliams J. Christopher^ORCID,Wiglesworth Kristin E.,Girard Kevin P.,Makowski Teresa M.,Sach Neal W.¹,Mustakis Jason G.,Mehta Ruchi,Trujillo John I.,Chen Xiaofeng²,Li Tangqing²,Shi Feng²,Xie Chengfu²,Zhang Qing²

Affiliation:

1. La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States

2. STA Pharmaceutical Co. Ltd., 90 Delin Road, Waigaoqiao, China (Shanghai) Free Trade Zone, Shanghai 200131, China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.9b00198

Reference13 articles.

1. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

2. bBrown, M. F.; Casimiro-Garcia, A.; Che, Y.; Coe, J. W.; Flanagan, M. E.; Gilbert, A. M.; Hayward, M. M.; Langille, J. D.; Montgomery, J. I.; Telliez, J.B.; Thorarensen, A.; Unwalla, R. J. Pyrrolo[2,3-d]pyrimidinyl- pyrrolo[2,3-b]pyrazinyl- and pyrrolo[2,3-d]pyridinylacrylamides as JAK inhibitor and their preparation WO 2015083028.

3. Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata. https://www.businesswire.com/news/home/20180905005542/en/Pfizer-Receives-Breakthrough-Therapy-Designation-FDA-PF-06651600. Accessed on April 28, 2019.

4. Asymmetric Hydrogenation of Six-Membered Monocyclic N-Heteroaromatic Compounds

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12

2. Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata;Expert Opinion on Drug Metabolism & Toxicology;2024-09-09

3. Unravelling the Impact of Process Impurities on the Crystallization of Ritlecitinib Tosylate Using Molecular Dynamics;Organic Process Research & Development;2024-09-09

4. Modular and Diverse Synthesis of Acrylamides by Palladium‐Catalyzed Hydroaminocarbonylation of Acetylene;Angewandte Chemie;2024-09-03

5. Modular and Diverse Synthesis of Acrylamides by Palladium‐Catalyzed Hydroaminocarbonylation of Acetylene;Angewandte Chemie International Edition;2024-09-02